Illumina lowers profit forecast due to ongoing biotech funding challenges.
Illumina lowers profit forecast due to ongoing biotech funding challenges.
Illumina Inc Cuts Profit Forecast Amid Funding Crunch in Biotech and Pharmaceutical Sector
/cloudfront-us-east-2.images.arcpublishing.com/reuters/T6BNM4HBWBPB3MOMJ7ZD3LB7BY.jpg)
Aug 9 (ANBLE) – Illumina Inc (ILMN.O) has recently announced a cut in its annual profit forecast. This news comes as no surprise to many, as a funding crunch has been affecting its biotech and pharmaceutical clients, which in turn is expected to weigh down on the sales of its genetic testing tools and diagnostic products. Analysts have called this a clear indication of the impact that rising interest rates and the collapse of key investment bank Silicon Valley Bank are having on small biotech firms, especially in China.
Shares of Illumina dropped by nearly 6% in extended trading on Wednesday, reflecting the overall uncertainty surrounding the situation. However, it’s not all doom and gloom for the company. Although the funding crunch poses challenges, higher-than-expected demand for their production-scale sequencer, NovaSeq X, has helped to surpass Wall Street estimates for second-quarter profit.
In terms of financial performance, Illumina reported an adjusted profit of 32 cents per share for the second quarter, greatly surpassing the expected 2 cents per share. Furthermore, the company recorded total sales of $1.18 billion for the quarter ended July 2, exceeding the anticipated $1.16 billion. These figures are impressive and highlight the resilience of Illumina despite the ongoing challenges.
However, looking ahead, Illumina has adjusted its full-year profit per share forecast to be between $0.75 and $0.90, compared to the previous forecast of $1.25 to $1.50. This modification is due to various factors, including a tax expense impact of around $75 million. Nevertheless, the company is actively taking measures to mitigate the effects of sticky inflation, a strong dollar, and an ongoing litigation related to its $7.1 billion repurchase of Grail in 2021.
To navigate the uncertain times, Illumina plans to save costs by cutting jobs and closing some offices. These cost-saving measures are essential to cushioning the impact of unfavorable market conditions. Additionally, the company is currently engaged in a proxy battle with activist investor Carl Icahn and is in search of a new CEO after the departure of former chief Francis deSouza in June.
- Pilot Shortages Affect Passengers
- DC Democrats oppose implementing ranked choice voting, claiming it ...
- Ohio Dems. chair mocks Republican for complaining about lack of tim...
Overall, it is evident that Illumina is facing headwinds in the biotech and pharmaceutical sector as a result of the funding crunch. However, the company’s ability to surpass expectations in certain areas demonstrates its resilience and adaptability. As the industry recovers and conditions stabilize, it remains to be seen how Illumina will navigate these challenging times and emerge as a leader in genetic testing and diagnostics.
| Metric | Q2 2022 | Expected |
|---|---|---|
| Adjusted profit/share | $0.32 | $0.02 |
| Total sales | $1.18 billion | $1.16 billion |
List: Illumina’s Key Challenges and Measures
- Funding crunch among biotech and pharmaceutical clients
- Impact of rising interest rates
- Collapse of U.S. lender Silicon Valley Bank
- Adjusted profit per share forecast cut to $0.75-$0.90
- Tax expense impact of approximately $75 million
- Efforts to save costs through job cuts and office closures
- Ongoing litigation related to the Grail repurchase
- Proxy battle with activist investor Carl Icahn
- Search for a new CEO
Disclaimer: The information provided here is based on the available data and sources. Please conduct further research or consult professionals for detailed financial analysis and advice.
